The bio-tech major, Moderna, received mixed news recently. GSK expanded mRNA patent litigation against Moderna's next-gen COVID shot seeking royalties, while Pfizer, Moderna, and Novavax praised the Warp Speed program's success. Simultaneously, RFK Jr. cancelled his $500m funding for US mRNA vaccine research, a significant blow according to the WHO. Despite this, both Moderna and Pfizer secured restricted FDA approval for their updated mRNA COVID vaccines.
Meanwhile, Moderna and IBM simulated the longest mRNA pattern using a quantum computer. Further, CVS Health and Walgreens altered COVID vaccine policies because of new FDA guidelines. In other sectors, Moderna scrapped plans to establish mRNA plant in Japan, and Comerica Bank purchased 29,020 Moderna shares. On another note, the USPTO adjudicated two of Moderna's mRNA patents unpatentable, causing uncertainty for the 'vaccine wars'.
Moderna's mRNA seasonal flu vaccine showed promising phase 3 data, and its combo Covid and flu mRNA shot outperformed current vaccines in a large trial. Furthermore, it has gained a FDA nod for the next-gen COVID-19 vaccine targeting LP.8.1 variant. Despite facing RFK Jr.'s withdrawal from some mRNA vaccine deals, Moderna continues to forge ahead in the bio-tech landscape.
Moderna MRNA News Analytics from Fri, 25 Oct 2024 07:00:00 GMT to Sat, 06 Sep 2025 13:38:42 GMT - Rating 7 - Innovation 9 - Information 8 - Rumor -5
